EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
http://www.reportlinker.com/p01163173/EpiCast-Report-Cystic-Fibrosis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

Summary

Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that cases CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. GlobalData forecasts that the US and UK will have the most prevalent cases of CF in 2022. In 2022, the combined prevalent CF cases in the 5EU countries (France, Germany, Italy, Spain, and the UK) will be slightly larger than the number of prevalent CF cases in the US. The UK and France will have the greatest prevalence proportions (0.0157% and 0.0097%, respectively) and the largest 10-year growth (33.2% and 38.1%, respectively), implying that this may be the result of a higher prevalence of CF gene mutations in these populations. The high number of prevalent cases of CF in the US is due to all 50 states screening for CF in newborns. National CF screenings are imperative in detecting and capturing the true prevalence of the disease in a given country.

Scope

- The Cystic Fibrosis EpiCast Report provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK).
- It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age (segmented by five-year age groups, beginning at age 0 years and ending at ages 35 years and older), and mutation type (F508del, G551D, G54X, W1282X, 621+1G>1, R553X, and 3950delT).

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.
- Quantify patient populations in the global cystic fibrosis market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for cystic fibrosis therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 The occurrence of cystic fibrosis is approximately one in 2,500 Caucasians 9
3.1.2 Increased cystic fibrosis life expectancy increases comorbidities of CF-related diabetes and bone disease 9
3.2 Global Trends 10
3.2.1 United States 10
3.2.2 France 11
3.2.3 Germany 11
3.2.4 Italy 12
3.2.5 Spain 12
3.2.6 United Kingdom 13
3.3 Forecast Methodology 13
3.3.1 Sources Used 13
3.3.2 Forecast Assumptions and Methods 16
3.3.3 Sources Not Used 19
3.4 Epidemiology Forecast 19
3.4.1 Total Prevalent Cases of Cystic Fibrosis 19
3.4.2 Total Prevalent Cases of Cystic Fibrosis Segmented by Age 21
3.4.3 Total Prevalent Cases of Cystic Fibrosis Segmented by Sex 22
3.4.4 Total Prevalent Cases of Cystic Fibrosis by Mutation Type 23
3.5 Discussion 25
3.5.1 Conclusion on Epidemiology Trends 25
3.5.2 Limitations of the Analysis 25
3.5.3 Strengths of the Analysis 25
4 Appendix 26
4.1 Bibliography 26
4.2 About the Authors 31
4.2.1 Epidemiologists 31
4.2.2 Reviewers 31
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 33
4.2.4 Global Head of Healthcare 33
4.3 About GlobalData 34
4.4 About EpiCast 34
4.5 Contact Us 34
4.6 Disclaimer 35

List of Tables

Table 1: Six Major Markets, Sources of Cystic Fibrosis Prevalence Data 14
Table 2: Six Major Markets, Sources of Cystic Fibrosis-Causing Mutation Data 14
Table 3: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 20
Table 4: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, By Sex, 2012 , N (%) 22
Table 5: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 23

List of Figures

Figure 1: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 20
Figure 2: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, By Age, Males and Females, 2012 21
Figure 3: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 24

To order this report:
Pathology Industry: EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker